C4 Therapeutics Presents New Biomarker Data from the Cemsidomide Phase 1 Trial with Dexamethasone and Phase 1b Trial with Elranatamab (ELREXFIO®) in Relapsed/Refractory Multiple Myeloma at the 23rd International Myeloma Society (IMS) Annual Meeting
C4 Therapeutics, Inc CCCC
$2.98
▼ -1.65%
($-0.05)
🔥 High Short Interest
🎢 High Beta
Open
$3.03
Prev Close
$3.03
Day Range
$2.93 – $3.12
52W Range
$1.69 – $5.17
Market Cap
$366.61M
Beta
3.18
EPS (TTM)
$-1.00
📋 Company Profile
| Industry | Biotechnology |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 2020-10-02 |
| Shares Out. | 110,570,000 |
| Website | c4therapeutics.com/ ↗ |
| Phone | 13026587581 |
| Employees | 104 |
| Revenue | $6.6M |
| Gross Profit | $6.6M |
| Net Income | -$23.6M |
| Free Cash Flow | -$85.4M |
| Total Assets | $359.4M |
| Total Liabilities | $112.1M |
| Equity | $247.3M |
About C4 Therapeutics, Inc
C4 Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation science to create a new generation of medicines that transforms patient's lives. The Company is progressing targeted oncology programs through clinical studies and leveraging its TORPEDO platform to efficiently design and optimize small-molecule medicines to address difficult-to-treat diseases. The degrader medicines of the company are designed to harness the body's natural protein recycling system to rapidly degrade disease-causing proteins, offering the potential to overcome drug resistance, and drug undruggable targets and improve patient outcomes. Its pipeline is Cemsidomide, CFT8919, and other discovery products.
C4 Therapeutics, Inc is a publicly traded company under the ticker symbol CCCC on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
13 analysts (2026-09-01)